Oculis Holding AG (OCS)
Oculis Holding AG operates in the Biotechnology industry of the Healthcare sector, headquartered in Zug, ZG, CH. The stock last traded at $12.96, up 1.65% on the session, giving a market capitalisation of $740.9M. On trailing twelve-month figures it carries a trailing P/E of -6.09, a net margin of -18861.3%. Its beta of 0.23 implies it has historically moved less than the broad market.
Oculis Holding AG is a biopharmaceutical company in the clinical development stage, specializing in the creation of innovative eye drop medications for various ocular conditions, addressing both the anterior and posterior segments of the eye. A key asset in its therapeutic portfolio is OCS-01, a topical formulation of dexamethasone, currently progressing through Phase 3 clinical trials for the management of diabetic macular edema. Additionally, OCS-02, a topically administered biological candidate, is engaged in Phase 2b clinical studies to treat keratoconjunctivitis sicca, commonly known as dry eye disease. The company is also advancing OCS-05, an innovative neuroprotective agent, which targets acute optic neuritis and an array of other neuro-ophthalmic disorders, including glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. This enterprise maintains its headquarters in Zug, Switzerland.
Oculis Holding AG is most often compared with the following Healthcare names: